Safety of quadrivalent human papillomavirus vaccine
Article first published online: 11 DEC 2011
© 2011 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 271, Issue 2, pages 177–178, February 2012
How to Cite
Omer, S. B. (2012), Safety of quadrivalent human papillomavirus vaccine. Journal of Internal Medicine, 271: 177–178. doi: 10.1111/j.1365-2796.2011.02481.x
- Issue published online: 17 JAN 2012
- Article first published online: 11 DEC 2011
- Accepted manuscript online: 11 NOV 2011 11:12AM EST
- 1Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion. Cancer Among Women. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, 2011. 2-10-2011, 10-20-2011. Accessed on 15 November 2011 at http://www.cdc.gov/cancer/dcpc/data/women.htm.
- 2World Health Organization. Human Papillomavirus and HPV Vaccines: Technical Information for Policy-Makers and Health Professionals. Geneva: World Health Organization, 2007.
- 4Merck & Co., Inc. GARDASIL Package Insert. 11. Whitehouse Station: Merck & Co., Inc, 2011.
- 5CDC/National Center for Health Statistics. Death Rates by 10-Year Age Groups: United States and Each State, 1999–2007. Atlanta: CDC/National Center for Health Statistics, 2011. 10-8-2010, 10-20-2011.
- 6Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) & Division of Healthcare Quality Promotion (DHQP). Frequently Asked Questions about HPV Vaccine Safety. Atlanta: Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) & Division of Healthcare Quality Promotion (DHQP), 2011. 8-8-2011, 10-20-2011.
- 10National and state vaccination coverage among adolescents aged 13 through 17 years – United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60: 1117–23.